{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-007046","form_type":"8-K","ticker":"INKT","cik":"0001840229","company_name":"MiNK Therapeutics, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.629809+00:00","generated_at":"2026-06-22T09:51:08.359710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MiNK Therapeutics Q3 2022 net loss $6.3M, cash $24.2M; pipeline and R&D day updates","bullets":["Net loss $6.3M ($0.19/share) in Q3 2022 vs $14.3M ($0.59/share) in Q3 2021; nine-month loss $20.2M.","Cash $24.2M at Sep 30, 2022, down from $38.9M at Dec 31, 2021; cash used in ops $14.4M in nine months.","Five abstracts accepted at SITC 2022; R&D day Nov 10, 2022 featuring external experts.","R&D expenses rose to $6.15M from $3.33M in Q3 2021 due to internal cGMP manufacturing scale-up.","No revenue or guidance; clinical-stage biotech advancing allogeneic iNKT cell therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-007046","json":"https://secwatch.observer/filing/0001171843-22-007046.json","markdown":"https://secwatch.observer/filing/0001171843-22-007046.md","text":"https://secwatch.observer/filing/0001171843-22-007046.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840229/000117184322007046/0001171843-22-007046-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840229/000117184322007046/f8k_110322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:51:08.359710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"528ccfa958b2fd5d63c9d6dbaf1f043e87a07295","claim":"MiNK Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $6.3 million or $0.19 per share, EPS $0.19 per share.","evidence_excerpt":"Net loss for the quarter ended September 30, 2022, was $6.3 million or $0.19 per share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840229/000117184322007046/0001171843-22-007046-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$6.3 million or $0.19 per share"},{"label":"EPS","value":"$0.19 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}